Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
2036-A DEVELOPMENT OF A NOVEL CLINICAL SCREENING TOOL TO PREDICT LIVER FIBROSIS Madeleine Haff 1 , Na Wang 2 , Emily Kate Sisson 2 and Michelle Long 1,3 , (1)Boston Medical Center, Boston, MA, (2)Boston University, (3)Novo Nordisk Background: Nonalcoholic fatty liver disease (NAFLD) is a major contributor to liver disease in the United States, and non-invasive tools such as vibration-controlled transient elastography (VCTE) estimate the risk of liver fibrosis and help guide patient care
Supporting Energy Levels
Chang, H., et al
If your face swells immediately after your injections, asymmetry is normal
Supplier Info Centre
It comes from United States Pharmacopeia General Chapter 797, which sets a default beyond-use date for opened multi-dose vials of any kind
US$ 27.62
US$ 23.15
US$ 25.76
US$ 21.49
